Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of

Nathan W Kong1, Aakash Bavishi2, Ansel Philip Amaral2

  • 1Department of Internal Medicine, University of Chicago, Chicago, Illinois.

Insights

Patients with very high risk (VHR) of cardiovascular events have significantly higher event rates than high-risk (HR) patients. This study confirms VHR and HR stratification is crucial for effective secondary prevention strategies.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Health Outcomes Research

Background:

  • The 2018 ACC/AHA guidelines define "very high risk" (VHR) and "high risk" (HR) patient groups for secondary cardiovascular prevention.
  • Characterizing the incidence and risk differences between VHR and HR patients in real-world, non-trial settings is essential.

Purpose of the Study:

  • To compare the incidence of VHR and HR patients.
  • To evaluate the relative risk for cardiovascular morbidity and mortality between VHR and HR groups in a large, academic, retrospective cohort.

Main Methods:

  • Retrospective analysis of 1,483 patients with acute coronary events (2014-2016).
  • Risk stratification into VHR and HR groups based on guideline criteria.
  • Assessment of composite events (unstable angina, myocardial infarction, ischemic stroke, all-cause death) over a median 3.3-year follow-up using ICD codes.

Main Results:

  • VHR patients experienced 87 events per 1,000 patient-years versus 33 events per 1,000 patient-years in HR patients (p <0.001).
  • VHR patients had a 1.66-fold increased risk of future cardiovascular events compared to HR patients (aHR 1.66 [1.01–2.74], p=0.047).

Conclusions:

  • The findings support the clinical utility of stratifying patients into VHR and HR groups for secondary prevention.
  • This risk stratification aids in tailoring interventions for patients at different levels of atherosclerotic cardiovascular disease risk.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
510
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
246
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
160
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
135
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
730
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
157